Title :

Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.

Author(s) :

Palomba, Maria Lia [Auteur]
Memorial Sloane Kettering Cancer Center [New York]
Cartron, Guillaume [Auteur]
CHU Montpellier = Montpellier University Hospital
Popplewell, Leslie [Auteur]
City of Hope Comprehensive Cancer Center [Duarte]
Ribrag, Vincent [Auteur]
Institut Gustave Roussy [IGR]
Westin, Jason [Auteur]
MD Anderson Cancer Center [Houston]
Huw, Ling-Yuh [Auteur]
Genentech, Inc. [San Francisco]
Agarwal, Shefali [Auteur]
Shivhare, Mahesh [Auteur]
Roche Products Ltd
Hong, Wan-Jen [Auteur]
Genentech, Inc. [San Francisco]
Raval, Aparna [Auteur]
Genentech, Inc. [San Francisco]
Chang, Alice C. [Auteur]
Genentech, Inc. [San Francisco]
Penuel, Elicia [Auteur]
Genentech, Inc. [San Francisco]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Journal title :

Clinical Lymphoma, Myeloma & Leukemia

Abbreviated title :

Clin Lymphoma Myeloma Leuk

Volume number :

22

Pages :

504-512

Publication date :

2022-07

ISSN :

2152-2669

English keyword(s) :

Epigenetic
EZH2 inhibitor
Immunotherapy
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background The combination of atezolizumab, a monoclonal antibody that targets programmed death-ligand 1 (PD-L1) and inhibits the interaction between PD-L1 and its receptors, and tazemetostat, an EZH2 inhibitor, may lead ...
Show more >Background The combination of atezolizumab, a monoclonal antibody that targets programmed death-ligand 1 (PD-L1) and inhibits the interaction between PD-L1 and its receptors, and tazemetostat, an EZH2 inhibitor, may lead to selective epigenetic reprogramming, alter the tumor microenvironment, and provide additive or synergistic response to patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Materials and Methods This was an open-label, phase Ib study assessing the safety, tolerability, and preliminary efficacy of atezolizumab plustazemetostat in patients with R/R DLBCL. Atezolizumab (1200 mg) was administered via intravenous (IV) infusion on day 1 of each cycle and tazemetostat (800 mg) was given orally twice daily (BID) on days 1 to 21. Primary endpoints were safety and tolerability, and to identify a recommended phase II dose (RP2D) for atezolizumab. Secondary efficacy endpoints included response rate and duration of response. Results A total of 43 patients were enrolled, receiving a median of 3 prior lines of treatment (range: 1-9). The RP2D for atezolizumab was 1200 mg IV infusion every 3 weeks in combination with tazemetostat 800 mg BID. At the RP2D, adverse events reported in ≥20% patients were anemia(11 patients [26%]), fatigue (10 patients [23%]), and nausea (10 patients [23%]). Overall response rate was 16% (complete response rate: 7%). Median progression-free survival was 2 months (range: 0-24) and median overall survival was 13 months (range: 1-29). Conclusions The combination of atezolizumab and tazemetostat was determined to be safe and tolerable. However, anti-tumor activity of the combination was modest.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Submission date :

2023-05-25T02:44:34Z
2024-06-28T08:06:00Z